What Proscia Does
Proscia builds AI-powered digital pathology software for precision medicine. Its Concentriq platform serves two markets: clinical labs, where Concentriq AP-Dx gives pathologists AI-assisted case review and primary diagnosis tools, and life sciences, where Concentriq AP and LS enable biomarker research, clinical trials and companion diagnostics. The platform analyzes tissue images and pathology data to speed diagnostic decisions and drug development.
Scale and Recognition
Proscia serves more than 4,000 hospitals and clinics globally, manages roughly 12 million cases annually and is trusted by 16 of the top 20 pharmaceutical companies, including Bayer, Gilead, Eli Lilly and Bristol Myers Squibb. The company was rated Best in KLAS 2026 for digital pathology platforms in both the US and Europe. Proscia raised $50M in 2025 and received US FDA clearance for AI-assisted colon polyp detection in primary diagnosis.